Clinical trial
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
NCT00111761 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111761 |
|---|---|
| Title | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer |
| Official title | A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | Irinotecan, Panitumumab, 5-Fluorouracil, Leucovorin |
| Enrollment | 43 |
| Start date | Jul 1, 2002 |
| Primary completion | Feb 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | May 26, 2005 |
| Last update posted | Dec 12, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: